Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

re treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... USA (PRWEB) September 16, 2014 “Nature ... create the features that we desire in optical design,” ... at Montana State University. “As we explore surfaces and ... of those lessons were presented in San Diego in ... Light: Light in Nature ” chaired by Shaw and ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... European Commission,s Joint Research Centre (JRC) has just ... a representative range of 25 different types of ... ensure consumer protection and confidence in many innovative ... most promising technological developments. By enabling a harmonised ...
... Feb. 14, 2011 New England Biolabs has expanded its ... One Taq Hot Start DNA Polymerases. Optimized blends of ... these new products offer robust amplification across a wide range ... exonuclease activity of Deep Vent increases the fidelity and robustness ...
... N.C., Feb. 14, 2011 India,s premier CRO, ... Society of India & Congress of Neurological Surgeons ...  The event was a convergence of leading neuroscientists, ... across the globe to discuss advances made in ...
Cached Biology Technology:Small material, big impact 2New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India 2
(Date:9/16/2014)... Health at the Mailman School of Public Health are ... and prenatal exposure to two phthalates used in a ... the journal Environmental Health Perspectives . , ... levels of the chemicals, butylbenzyl phthalate (BBzP) and di-n-butyl ... increase in risk of developing asthma between age 5 ...
(Date:9/16/2014)... maternal morbidity amongst women in Australia is increased ... published today (17 September) in BJOG: An ... Australians generally enjoy high standards of living; however, ... in particular between indigenous and non indigenous Australians. ... independent impact of socioeconomic position on severe maternal ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... Cambridge, Mass. - August 10, 2011 - Between conception ... meters long, looping and coiling within the tiny abdomen. ... loops into the same formationhowever, until now, it has ... experimental observations, biological and biophysical manipulations, theory, and computation, ...
... help overcome a major barrier to the use of gene ... reported development and successful initial laboratory tests of such a ... David Kaplan and colleagues note that gene therapy ... requires safe and efficient carriers or "vectors." Those carriers ...
... , Working out the structure of a complex formed ... be key in understanding how an antibiotic-producing organism controls ... example of how other antibiotic producers regulate export to ... certain microorganisms is a complex and highly regulated process, ...
Cached Biology News:Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3
... esters have moderate chemiluminescence efficiencies and the ... They have the added benefit that they ... to the background signal. This benefit has ... sensitivity immunoassay applications. These compounds can also ...
... Kit for Kilo-Sequencing is designed to aid ... into the multiple cloning sites (MCS) of ... or phagemid vectors (pUC18/19). The kit is ... the target DNA, thereby progressively moving the ...
... client/server version of Freezerworks Unlimited includes 2 clients ... and facilitates the sharing of freezers by multiple ... Network Client/Server ... 13 in monitor with 256 colors; OS 8.6 ...
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: